Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa BrainshuttleTM AD study and design of Phase III PrevenTRON study in preclinical Alzheimer’sNew data on Roche’s CE mark Elecsys pTau217 blood test will be presented on its use for Alzheimer's diagnosis in both primary and secondary care Basel, 7 July 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference® 2026 (AAIC®) in London on 12-15 July. These data demonstrate how Roche is advancing the development…